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Abstract: The specific targeting of protein-protein interactions by 
phosphoserine-containing small molecules has been scarce due to 
the dephosphorylation of phosphoserine and its charged nature at 
physiological pH, which hinders its uptake into cells. To address these 
issues, we herein report the synthesis of phosphoserine aryloxy 
triester phosphoramidates as phosphoserine prodrugs, which are 
enzymatically metabolized to release phosphoserine. This 
phosphoserine masking approach was applied to a phosphoserine-
containing inhibitor of 14-3-3 dimerization, and the generated 
prodrugs exhibited improved pharmacological activity. Collectively, 
this provided a proof of concept of the masking of phosphoserine with 
biocleavable aryloxy triester phosphoramidate masking groups as a 
viable intracellular delivery system for phosphoserine-containing 
molecules. Ultimately, this will facilitate the discovery of 
phosphoserine-containing small molecule therapeutics. 
Protein phosphorylation at serine residues is a fundamental 
phenomenon that is used by cells to affect the function, 
localization and degradation of proteins.[1] In some cases, 
phosphorylated serine residues mediate protein-protein 
interactions via the docking of the phosphoserine residue into 
a positively charged pocket within the partner protein. An 
example of this is the serine phosphorylation of the adaptor 
protein 14-3-3, which facilitates its homodimerization.[2] 
Attempts at inhibiting these phosphoserine-mediated 
protein-protein interactions with small molecules have mostly 
led, by design, to small molecules that lack phosphoserine. 
The move to discard phosphoserine groups from these 
molecules was driven by the fact that phosphoserine carries 
two negative charges at physiological pH, which limit its 
(passive) cellular uptake.[3] Additionally, phosphoserine is 
also subject to dephosphorylation by alkaline phosphatases, 
a process that yields serine-containing derivatives that do not 
often retain potent pharmacological activity compared to their 
parent phosphoserine-containing molecules. Although the 
masking of the phosphate group of phosphoserine was 
previously investigated, the study was limited to a 
phosphoserine mimetic (difluoromethylenephosphoserine) 
and not the natural phosphoserine moiety.[4] With this in mind 
and in order to improve the drug-like properties of 
phosphoserine-containing small molecules, we explored the 
application of the aryloxy triester phosphoramidate 
technology to phosphoserine. This technology has been 
widely used to mask the 5’-O-monophosphate groups of 
nucleotides, and has so far led to two FDA-approved drugs; 
sofosbuvir and tenefovir alafenamide.[5]  
As a proof of concept, we initially synthesized phosphoserine with 
the aryloxy triester phosphoramidate masking groups (Figure 1a). 
For this, the N- and C-terminals of phosphoserine had to be 
protected[6] first to allow for the selective addition of the aryloxy 
triester phosphoramidate moiety to the side chain hydroxyl group. 
The synthesis was initiated by the chlorination of tert-butanol (1) 
by copper(I) chloride with the peptide coupling reagent N,N'-
dicyclohexylcarbodiimide (DCC).[6] The generated compound, 2, 
was then reacted with the commercially available N-Boc L-serine, 
3, in DCM to yield the N- and C-protected L-serine 4.[6] This latter 
compound was subsequently reacted with phenyl L-alanine 
methyl ester phosphorochloridate (7), which had been 
synthesized according to reported procedures[7] by reacting L-
alanine methyl ester hydrochloride (6) with the commercially 
available phenyl dichlorophosphate (5) in DCM and in the 
presence of triethylamine (NEt3). This reaction yielded the desired 
phosphoserine aryloxy triester phosphoramidate, compound 8, as 
a white solid in a good yield (62%). 
With the phosphoserine aryloxy triester phosphoramidate in hand, 
we first studied whether the aryl and amino acid ester groups that 
mask the phosphate group of phosphoserine could be 
metabolized in vitro to release the unmasked phosphoserine 
species. It is now well established that the metabolism of the 
aryloxy triester phosphoramidate moieties is  initiated by the 
cleavage of the ester motif by carboxypeptidase Y to yield 
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metabolite A (Figure 1b).[5a, 8] The formed carboxylate group then 
performs a nucleophilic attack onto the phosphate group leading 
to the release of the aryl group and the formation of a highly 
unstable five-membered anhydride ring (metabolite B, Figure 1b). 
This is subsequently opened up by a water molecule to generate 
the phosphoramidate metabolite C (Figure 1b). Finally, the 
phosphoramidase-type enzyme Hint-1[9] cleaves the P-N bond of 
metabolite C to release the unmasked monophosphate group. 
With this in mind, we incubated compound 8 at 37 °C with 
commercially available recombinant carboxypeptidase Y and 
monitored the sample by 31P-NMR (Figure 1c).  
As shown in Figure 1c, at t = 0 min, the 31P-NMR of 
compound 8 shows a sharp two singlets (dp = 3.1 and 3.2 
ppm), which correspond to the two diastereoisomers (R and 
S) of the phosphoserine aryloxy triester phosphoramidate. 
This is typical of the aryloxy triester phosphoramidates as 
they have a chiral phosphorous and most current synthetic 
routes yield these compounds as a mixture of two 
diastereoisomers.[5a, 7b, 10] After 5 minutes incubation with 
recombinant carboxypeptidase Y, two new peaks appeared; 
one appeared briefly at dp = 4.1 ppm while another peak at 
dp = 6.4 ppm also appeared and remained throughout the 
rest of the experiment. This is typical for aryloxy triester 
phosphoramidates as previous studies using 
carboxypeptidase Y showed a similar pattern with the peak 
at  dp = 4.1 ppm corresponding to metabolite A whilst that at 
dp = 6.4 ppm corresponding to metabolite C (Figure 1b).[10-
11] Notably, after 30 minutes incubation, only the 31P-NMR 
peak at dp = 3.2 ppm remained from the two 31P-NMR peaks 
of the parent compound 8. This indicated that one of the 
diastereoisomers of phosphoserine phosphoramidate, which 
has a 31P-NMR that corresponds to dp = 3.1 ppm, is a better 
substrate for the enzyme and thus was processed quicker. 
From 30 minutes onward, only two 31P-NMR peaks persisted; 
dp = 3.2 and 6.4 ppm. After 18 h, the peak at dp = 6.4 ppm 
became the major peak with only one of the peaks from the 
original phosphoserine phosphoramidate two singlets 
remained. Mass spectrometry analysis of the products 
generated from this in vitro enzymatic assay after 18 h 
confirmed the breakdown of the phosphate masking groups 
and the release of metabolite C (Supporting Figure S1). As 
in this in vitro assay, there was no phosphoramidase-type 
enzyme, metabolite C was not further processed to release 
the fully unmasked phosphoserine species. To predict 
whether metabolite C would be a good substrate for Hint-1, 
we performed in silico docking of the metabolite into the 
crystal structure of the human Hint-1 co-crystallized with 
AMP (PDB 1KPF) as previously reported.[10] The results 
showed that metabolite C sits in the Hint-1 active site and the 
phosphate group of phosphoserine  forms key interactions 
with catalytic residues of Hint-1 (serine107, histidine112 and 
histidine114) suggesting that it could be a good substrate for 
this enzyme (Supporting Figure S2).[9b] These docking 
results are in line with previous docking studies for the same 
enzyme that predicted and verified whether the P-N bond of 
the docked substrates  could be cleaved off by Hint-1.[9b] 
Together, these results indicate that phosphoserine aryloxy 
triester phosphoramidates are metabolized in a similar 
fashion to the nucleoside monophosphate aryloxy triester 
phosphoramidates.  
In order to establish the applicability of the aryloxy triester 
phosphoramidate approach in improving the 
pharmacological activity of phosphoserine-containing 
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Fig. 1. Synthesis and in vitro esterase-mediated metabolism of phosphoserine aryloxy triester phosphoramidates. A. Synthesis of a phosphoserine aryloxy triester 
phosphoramidates (8). B. Mechanism of aryloxy triester phosphoramidates metabolism. C. 31P-NMR in vitro enzymatic assay of the breakdown of the 
phosphoserine phosphoramidate by carboxypeptidase Y.  
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dimerization inhibitor 13 (Figure 2), which showed 
promising, but not potent activity in cells.[12] This compound 
is an ideal candidate for the application of the aryloxy triester 
phosphoramidate technology as it contains a phosphoserine 
motif that is essential for its pharmacological activity.[12]  
The synthesis of the aryloxy triester phosphoramidates of 
compound 13 commenced by the regioselective benzylation 
of the side chain hydroxyl group of N-Boc-L-serine (3), which 
proceeded with 70% yield (Figure 2a). The carboxylic acid 
of the product, 9, was then conjugated to the amine group of 
tyramine to form a peptide bond using the peptide coupling 
reagent PyBOP in THF in the presence of NEt3. This was 
then followed by sequential deprotection of the amine group 
and the side chain hydroxyl moiety using trifluoroacetic acid 
in DCM and hydrogenation, respectively. This resultant 
compound 11 was reacted with compound 18, which had 
been generated[13] in two steps from the commercially 
available 4-azidobenzoic acid (Figure 2b), to generate 
compound 12.  
For the synthesis of the reported 14-3-3 dimerisation 
inhibitor, 13, compound 12 was reacted with N,N,N’,N’-
tetramethylphosphorodiamidic chloride in MeCN in the 
presence of the Grignard reagent tertbutyl magnesium 
chloride (tBuMgCl). The generated phosphorodiamidate 
derivative was then converted to the desired monophosphate 
species, 13, by treatment with HCl in dioxane. We also 
synthesized the derivative of compound 13 where the 
phosphate group is fully masked by diethyl groups, 
compound 14, to be used as a negative control in the 
biological assays. The synthesis was achieved by reacting 
compound 12 with diethyl chlorophosphate in the presence 
of tBuMgCl in MeCN to flourish the desired compound 14 in 
30% yield. For the synthesis of the aryloxy triester 
phosphoramidates of the 14-3-3 dimerization inhibitor, 13, 
the synthesis was accomplished by coupling compound 12 
to the appropriate phosphorochloridate (7, 20a or 20b, 
Figure 2c) in the presence of tBuMgCl in MeCN to give the 
desired aryloxy triester phosphoramidates (15a-c), as a 
mixture of two diastereoisomers, in low yields (~ 30%). 
Notably, the phosphorochloridates 7, 20a-b were 
synthesised as shown in Figure 2c and reported 
previously.[7]  
In order to determine the efficacy of the synthesized aryloxy 
triester phosphoramidate prodrugs to inhibit 14-3-3 
dimerization and cell proliferation, we treated the lung cancer 
cell line, A549, with the 14-3-3 dimerization inhibitor, 13, its 
diethyl phosphate derivative, 14, and the aryloxy triester 
phosphoramidates 15a-c as well as compound 12 at the 
indicated concentrations (12.5, 25, 50 and 100 µM) for 48 
and 72 h (Figure 3). Cell viability was then determined using 
standard MTT assays. The results showed that, as expected, 
the unphosphorylated compound 12, its phosphorylated 
derivative 13 and the diethyl phosphate compound 14, did 
not show any significant effect on cell viability. 
Encouragingly, the aryloxy triester phosphoramidates 15a-c, 
apart from 15a, did show significant dose-dependent 
reduction of A549 cell viability (Figure 3). This is because 
these aryloxy triester phosphoramidates are neutral at 
physiological pH, unlike the parent compound 13, and thus 
they are more readily taken up by cells via passive diffusion. 
The fact that among this series of aryloxy triester 
phosphoramidates, the isopropyl and benzyl ester 
phosphoramidates (15b and 15c, respectively) showed 
significant biological activity and the methyl ester 
phosphoramidate, 15a, did not demonstrate profound 
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13: R1 = R2 = OH.
14: R1 = R2 = Et.
15a: R3 = Me (29%).
15b: R3 = iPr (27%).
15c: R3 = Bn (29%).






















7: R4 = Me (84%).
20a: R4 = iPr (85%).
20b: R4 = Bn (83%).
L-alanine amino acid 
ester hydrochloride
1) For compound 13:
a. N,N,N',N'-Tetramethylphosphorodiamidic 
chloride, tBuMgCl, MeCN, 24 h, 25%.
b. HCl, dioxane, 24 h, 99%.
2) For compound 14: 
Diethyl chlorophosphate, tBuMgCl, 
MeCN, 24 h, 30%.
7, 20a-c, tBuMgCl, MeCN, 24 h.
Fig. 2. A. Synthesis of the phosphoserine-containing 14-3-3 dimerization inhibitor (13), diethyl phosphate (14) and its aryloxy triester phosphoramidates (15a-c). 
The serine motif is shown in red while its phosphate and masked phosphate groups are shown in blue. B. Synthesis of the intermediate 2-((4-
azidobenzoyl)oxy)acetic acid (18). C. Synthesis of phenyl L-alanine ester phosphorochloridates (7 and 20a-b).  
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activity relationship of aryloxytriester phosphoramidates of 
5’-O-nucleoside monophosphates.[5a, 7b]  
In summary, masking the phosphate group of phosphoserine 
with an aryl motif and an amino acid ester serves as a useful 
approach for the intracellular delivery of phosphoserine. 
Indeed, this work showed using a combination of in vitro 
enzymatic and in silico docking studies that these 
phosphoserine aryloxy triester phosphoramidates are 
metabolized to release the unmasked phosphoserine moiety. 
The application of this approach to a 14-3-3 phosphoserine-
containing molecule significantly improved its 
pharmacological efficacy in cancer cells. Together, this 
validates this approach of phosphoserine masking with 
biocleavable motifs, and  this will in the future facilitate the 
discovery of phosphoserine-containing molecules as 
powerful tool compounds and potential therapeutics.  
Experimental Section 
Experimental details are found in the Supporting Information. 
Keywords: Phosphoserine • Phosphoramidate • Prodrug • 14-3-
3 • Cancer 
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Fig. 3. Cell viability of the unmasked phosphoserine compound (12), phosphoserine-containing 14-3-3 dimerization inhibitor (13), its diethyl phosphate derivatives 
(14) and the aryloxy triester phosphoramidates (15a-c). Cell viability was determined by standard MTT assay. The compounds were incubated with A549 lung 
cancer cell line for 48 h (white bar) and 72 h (grey bar) at the indicated concentrations. The percentage of cell viability was calculated and presented as normalized 
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The development of phosphoserine-containing therapeutics has been limited by their poor drug-like properties. To address this, we 
applied the aryloxy triester phosphoramidate prodrug technology to phosphoserine and a phosphoserine-containing 14-3-3- 
dimerization inhibitor. These prodrugs exhibited improved biological activity highlighting the promise of this prodrug technology in the 
discovery of phosphoserine-containing therapeutic.  
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I. SUPPORTING FIGURES 
 
Supporting Figure S1. A negative mode mass spectrometry spectra of the mixture from compound 8 
with carboxypeptidase Y after 18 h at 37 °C. The results show the presence of metabolite C, which has a 
mass of 412.3 g/mol. 
 
 




Supporting Figure S3. Docking of metabolite C into the crystal structure of the human HINT1 (PDB 
1KPF). The docking shows the close proximity of the phosphate group of metabolite C and its masking 
group to the HINT1 catalytic residues Ser107, His112 and His114.  
 
 
II. REAGENTS AND METHODS 
All solvents used were received from commercial suppliers. All of the other reagents used in the synthesis were 
purchased from Sigma-Aldrich, Fisher Scientific, Fluorochem, Alfa-Aesar or Carbosynth. All reactions were carried 
out under an argon or nitrogen atmosphere unless stated otherwise.  All glassware was oven-dried overnight and 
allowed to cool under dry argon/nitrogen. Thin Layer Chromatography (TLC). Reactions were monitored with 
analytical TLC on Merck silica gel 60-F254 precoated aluminium plates of 0.2 mm thickness. Plate visualisation was 
carried out with UV (254 nm), potassium permanganate stain (with heating) or phosphomolybdic acid stain (with 
heating). Flash Column Chromatography. Column chromatography was performed on silica gel (35−70 μM) as a 
stationary phase and with the described solvent system. Glass columns were slurry-packed under gravity and 
fractions withholding product were identified by TLC analysis or 31P NMR analysis. Nuclear Magnetic Resonance 
Spectroscopy. NMR spectra data were recorded on a Bruker AVIII300 (1H, 300 MHz; T = 295 K. 19F, 300 MHz; T = 
295 K. 31P, 121 MHz; T = 295 K), AVIII400 (13C, 101 MHz; T = 295 K) or a Bruker Avance 500 (1H, 500 MHz; T = 295 
K. 13C, 125 MHz; T = 295 K. 19F, 407 MHz; T = 295 K. 31P, 202 MHz; T = 295 K) spectrometer in the deuterated 
solvents indicated where the spectra were calibrated on residual solvent peaks. Chemical shifts (δ) are quoted in 
ppm (parts per million), and J values are quoted in Hz. In reporting spectral data, the following abbreviations were 
used: s (singlet), d (doublet), dd (doublet of doublet), t (triplet), q (quartet) and m (multiplet). 1D 13C NMR spectra 
was recorded using PENDANT pulse sequences. Mass Spectrometry. EI mass spectra was recorded on a VG 
ZabSpec magnetic sector mass spectrometer by the analytical staff and facilities at the School of Chemistry, 
University of Birmingham. ES mass spectra was manually recorded on a Bruker microtof mass spectrometer, 
operating in positive or negative ion modes. High resolution mass spectrometry was performed as a service by 
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Bath University, using a 6545 LC/Q-TOF mass spectrometer. High Performance Liquid Chromatography. HPLC was 
carried out on a DIONEX summit P580 quaternary low-pressure gradient pump with a built-in vacuum degasser 
using a Summit UVD 170s UV/vis multichannel detector. Solvents were used as HPLC grade and not purified 
further. Chromeleon software was used to visualize and process the obtained chromatograms. Analytical 
separations used a flow rate of 1 mL/min. Unless otherwise stated, all tested compounds had a purity of ≥95% as 
shown by HPLC. 
Cell treatment and MTT assay. A549 cells were cultured in Ham’s F12K (Kaighn’s) medium (TermoFisher) 
supplemented with 10% Fetal Bovine Serum (FBS) (Gibco) and 1% of PenStrep (Gibco). The cells were maintained 
at 37 °C in the incubator with 5% CO2 to reach 70-80% confluency to be used in the experiment. In 96-well plate, 
50 µL of complete growth media was added to each well. Each compound was prepared in a concentration of 400 
µM to reach the final concentration of 100 µM for the highest concentration after several dilutions. Afterwards, 
50 µL of each compound solution was mixed with the 50 µL of growth media in the first well. Serial dilution (2x 
dilution each step) was then performed by pipetting out 50 µL of each compound solution from the first well and 
pipetted in the next well, which contains 50 µL growth media and so on until the last well (11th well). The series 
of final concentration was ranging from 100 µM to 0.10 µM, and all compounds were prepared in triplicates. A 
50 µL of A459 cells containing 5,000 cells were added to each well, which contained 50 µL of compounds solution 
in the growth medium. The 96 well plates were incubated at 37 °C in the incubator with 5% CO2 for 48 and 72 hr 
before the MTT assay was performed. The MTT assay was performed using a CellTiter 96 Non-radioactive 
Proliferation Assay Kit (Promega). A 15 µL dye solution was then added on each well. After incubation for 4 hr at 
37 °C in the incubator with 5% CO2, 100 µL of stop solution was added to each well. The plates were then left 
overnight in room temperature before the absorbance was read on the microplate reader at 570 nm wavelength. 
As a control, DMSO was included in the experiments with 100% DMSO as the highest final concentration following 
serial dilution steps as the compounds. The same set of plates without cells (as a blank) were also measured its 
absorbance to be used for correcting the absorbance of the sample. Finally, the measured absorbance was then 





Carboxypeptidase Y Assay. The procedure was adapted from Mehellou et al.1 Compound 8 (5.0 mg) was dissolved 
in acetone-d6 (0.52 mL), followed by addition of Trizma buffer (0.64 mL, pH 7.4). After recording a control 31P 
NMR spectrum containing compound 8 in acetone-d6 and buffer, defrosted Carboxypeptidase Y (0.3 mg dissolved 
in 0.27 mL of Trizma buffer), purchased from Sigma-Aldrich UK, was added to the mixture. A 31P-NMR was then 
run immediately after the addition and then at even time intervals over 11 hr. The sample was then analysed by 
31P-NMR after 18 h. All 31P NMR spectra were recorded at 37 °C (±1). 
Molecular docking. PC Windows 7 with Intel Core i7-4790/3.6GHz microprocessor, 16 GB RAM, and 64 bit 
operating system was used to execute the computational studies. Docking was performed applying the molecular 
modelling modules, namely, Omega2, FRED, and VIDA provided by OpenEye Scientific Software 
(http://www.eyesopen.com). The three-dimensional crystal structure of the co-crystallized AMP with the human 
Hint1 was retrieved from the Protein Data Bank (PDB code 1KPF),2 and the active site was subsequently identified 
on the basis of the bound ligand. Multiple conformers for metabolite C were generated by Omega2 using the 
default settings.3 FRED (fast rigid exhaustive docking) implements a rigid docking approach to fit these conformers 
into the predefined binding site and rank the poses by scoring functions.4, 5 The VIDA module was then used to 
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visualize and inspect the docked poses within the receptor’s active site and to identify the main interacting 
residues. 
 
III. SYNTHETIC PROCEDURES 
tert-Butyl (tert-butoxycarbonyl)-L-serinate (4). tert-Butanol (3.13 g, 42.23 mmol), DCC (6.10 g, 29.56 
mmol) and copper(I)-chloride (0.031 g, 0.000313 mmol) were stirred under exclusion of light at 30 °C 
for 5 days to generate 2-chloro-2-methylpropane (2). The mixture was then diluted with anhydrous 
dichloromethane (20 mL) and a solution of N-tert-butyloxycarbonyl-L-serine (3) (2.0 g, 9.746 mmol) in 
anhydrous dichloromethane (16 mL) was added at 0 °C. The mixture was then allowed to warm to ambient 
temperature and stirred overnight. The solvent was subsequently removed in vacuo and the crude 
underwent flash chromatography (ethyl acetate:hexane 0:1 to 3:2) to yield compound 4 as a crystalline 
solid (1.272 g, 50%). δH (500 MHz, CDCl3) 5.44 (s, 1H), 4.28 (s, 1H), 3.92 (m, 2H), 2.41 (m, 1H), 1.51 
(s, 9H), 1.47 (s, 9H). δC (500 MHz, CDCl3) 176.56, 169.70, 82.74, 80.36, 64.19, 56.44, 28.31, 28.01. MS 
(ES+) m/z 262.20 [M+H]+ and 284.18 [M+Na]+. 
Methyl (chloro(phenoxy)phosphoryl)-L-alaninate (7). To a stirring solution of the commercially 
available phenyl dichlorophosphate 5 (0.35 mL, 2.370 mmol) and anhydrous DCM (10 mL), in a flame 
dried flask, was added L-alanine methyl ester hydrochloride 6 (301 mg, 2.155 mmol) and stirred for 15 
minutes at room temperature, under an argon atmosphere. Anhydrous triethylamine (0.62 mL, 4.262 
mmol) was added dropwise to the yellow solution at -78 oC to form a suspended white precipitate. The 
reaction mixture was stirred for 30 minutes before being left to stir and warm to room temperature for 2.5 
hours. Upon reaction completion, the colourless solution was concentrated under reduced pressure and 
filtered with anhydrous diethyl ether. The yellow filtrate was concentrated under reduced pressure to 
afford a yellow oil, which was purified with column chromatography (ethyl acetate:hexane 6:4) to yield 
compound 7 as a colourless oil (505 mg, 84%). δH (300MHz, CDCl3) 7.37 (dd, J = 7.2, 2.1 Hz, 2H, H-3), 
7.29 – 7.23 (m, 3H, H-2 + H-4), 4.24 – 3.93 (m, 2H, H-5 + H-6), 3.78 (d, J = 5.2 Hz, 3H, H-9), 0.97 (dd, 
J = 6.4, 3.0 Hz, 3H, H-7). δP (121MHz, CDCl3) 7.91, 7.55. Analytical data is in agreement with literature 
values.6  
tert-Butyl-N-(tert-butoxycarbonyl)-O-((((S)-1-methoxy-1-oxopropan-2-yl) amino) (phenoxy) 
phosphoryl)-L-serinate (8). To tert-butyl (tert-butoxycarbonyl)-L-serinate 4 (1.181 g, 4.519 mmol), 
methyl (chloro(phenoxy)phosphoryl)-L-alaninate 7 (1.255 g, 4.519 mmol) in anhydrous dichloromethane 
(40 mL) under nitrogen atmosphere was added trimethylamine (1.39 mL, 1.006 g, 9.942 mmol) dropwise 
and left to stir at ambient temperature overnight. The solvent was subsequently removed in vacuo and the 
crude underwent flash chromatography (ethyl acetate:hexane 0:1 to 3:2) to yield compound 8 as a white 
solid (1.398 g, 62%). δP (500 MHz, CDCl3) 2.24, 2.12. δH (500 MHz, CDCl3) 7.23 (m, 2H), 7.11 (m, 3H), 
5.48 (m, 0.5H), 5.36 (m, 0.5H), 4.34 (m, 2H), 4.28 (m, 1H), 3.39 (m, 1H), 3.32 (m, 0.6H), 3.74 (m, 0.4H), 
3.66 (s, 1.8H), 3.61 (s, 1.2H), 1.39 (s, 4H), 1.38 (s, 5H), 1.36 (s, 4H), 1.35 (s, 5H), 1.30 (m, 3H). δC (500 
MHz, CDCl3) 173.50, 168.25, 155.33, 150.65, 129.61, 124.88, 120.17, 82.69, 79.94, 67.40, 54.31, 52.49, 
50.09, 28.28, 27.84, 20.86. MS (ES+) m/z 503.22 [M+H]+ and 525.21 [M+Na]+. 
O-Benzyl-N-(tert-butoxycarbonyl)-L-serine (9). Under a nitrogen atmosphere, N-(tert-
Butoxycarbonyl)-L-serine 3 (500 mg, 2.437 mmol) was dissolved in anhydrous DMF (10 mL) and cooled 
to 0 oC. NaH (215 mg, 5.361 mmol) was slowly added, followed by dropwise addition of benzyl bromide 
(0.35 mL, 2.949 mmol), producing evanescence. The white suspension was stirred at room temperature, 
for 10 hours. Upon reaction completion, water (100 mL) was slowly added to the orange solution and the 
product was then extracted into ethyl acetate (3 x 40 mL). The combined organic layers were dried over 
MgSO4, filtered and concentrated under reduced pressure to afford a yellow oil. The oil was purified by 
flash column chromatography (DCM:methanol 85:15) to afford ether 9 as a white solid (502 mg, 70%). 
δH (500MHz, CDCl3) 11.11 (s, 1H, H-7), 7.42 – 7.13 (m, 5H, H-11 + H-12 + H-13), 5.42 (d, J = 8.3 Hz, 
1H, H-4), 4.53 (s, 2H, H-9), 4.51 – 4.42 (m, 1H, H-5), 3.81 (d, J = 6.6 Hz, 2H, H-8), 1.45 (s, 9H, H-1). 
δC (126MHz, CDCl3) 175.5 (C=O), 155.8 (C=O), 137.3 (C-Ar), 128.5 (CH-Ar), 128.0 (CH-Ar), 127.9 
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(CH-Ar), 80.4 (C), 73.4 (CH2), 69.7 (CH2), 53.9 (CH), 28.3 (CH3). MS (ES-) m/z 294.2 [M-H]-, 589.3 
[2M-H]-. Analytical data is in agreement with literature values.7  
tert-Butyl (S)-(3-(benzyloxy)-1-((4-hydroxyphenethyl)amino)-1-oxopropan-2-yl)carbamate (10). To 
a stirring solution of compound 9 (502 mg, 1.699 mmol) in anhydrous THF (10 mL) was added 
triethylamine (0.43 mL, 3.048 mmol) and the resultant mixture stirred for five minutes. PyBOP (952 mg, 
1.829 mmol) and tyramine (230 mg, 1.676 mmol) were then added and the solution was left to stir for 12 
hours, at room temperature. The orange solution was concentrated to an orange oil and diluted with water 
(40 mL) and the product was extracted into ethyl acetate (3 x 40 mL). The combined orange organic 
layers were dried over MgSO4, filtered and concentrated under reduced pressure to afford an orange oil. 
The oil was purified by flash column chromatography (ethyl acetate:hexane 7:3) to yield the desired 
product 10 as a white solid (670 mg, 95%). δH (500MHz, CDCl3) 7.36 – 7.25 (m, 5H, H-9 + H-10 + H-
11), 6.97 (d, J = 8.0 Hz, 2H, H-17), 6.73 (d, J = 8.1 Hz, 2H, H-18), 6.48 (s, 1H, H-13), 6.03 (s, 1H, H-4), 
5.36 (bs, 1H, H-20), 4.48 (d, J = 11.7 Hz, 2H, H-7), 4.23 (s, 1H, H-5), 3.92 – 3.50 (m, 2H, H-6), 3.48 (t, 
J = 9.3 Hz, 2H, H-14), 2.69 (t, J = 6.9 Hz, 2H, H-15), 1.43 (s, 9H, H-1). δC (126MHz, CDCl3) 170.3 
(C=O), 154.6 (C=O), 154.6 (C-Ar), 137.4 (C-Ar), 130.4 (C-Ar), 129.8 (CH-Ar), 128.5 (CH-Ar), 128.0 
(CH-Ar), 127.8 (CH-Ar), 115.5 (CH-Ar), 73.4 (CH2), 69.9 (CH2), 65.9 (C), 41.1 (CH2), 34.7 (CH2), 28.3 
(CH3), 28.1 (CH). MS (ES+) m/z 437.2 [M+Na]+.  
 (S)-2-Amino-3-hydroxy-N-(4-hydroxyphenethyl)propanamide (11). Step One. Synthesis of (S)-2-
amino-3-(benzyloxy)-N-(4-hydroxyphenethyl)propanamide. Compound 10 (651 mg, 1.571 mmol) was 
dissolved in DCM (5 mL) and stirred with TFA (4 mL) at room temperature for three hours, producing 
evanescence. The dark red solution was then quenched with water (50 mL) and washed with DCM (1 x 
20 mL), which was used to remove any residual impurities. The aqueous layer was then basified to pH 
12 with 10% NaOH solution. The product was then extracted into ethyl acetate (3 x 30 mL) extraction. 
The colourless organic layers were combined, dried over MgSO4, filtered and concentrated under reduced 
pressure to afford the desired amine  as a white solid (480 mg, 97%). The product was used without 
purification. δH (500MHz, CD3OD) 7.33 – 7.22 (m, 5H, H-15 + H-16 + H-17), 7.00 (d, J = 8.0 Hz, 2H, 
H-4), 6.72 (d, J = 8.0 Hz, 2H, H-3), 4.47 (s, 2H, H-13), 3.57 (d, J = 4.9 Hz, 2H, H-7), 3.54 – 3.46 (m, 1H, 
H-10), 3.44 –  3.32 (m, 2H, H-12), 2.67 (t, J = 7.1 Hz, 2H, H-6). δC (126MHz, CD3OD) 170.2 (C=O), 
155.7 (C-Ar), 137.0 (C-Ar), 129.7 (C-Ar), 129.4 (CH-Ar), 129.4 (CH-Ar), 128.2 (CH-Ar), 127.8 (CH-
Ar), 114.9 (CH-Ar), 73.1 (CH2), 67.9 (CH2), 53.1 (CH), 41.0 (CH2), 34.0 (CH2). MS (ES+) m/z 651.3 
[2M+Na]+. 
Step Two. Synthesis of (S)-2-amino-3-hydroxy-N-(4-hydroxyphenethyl)propanamide (11). To a stirring 
solution of the intermediate amine (1.1 g, 3.499 mmol) in 1:1 mixture of anhydrous ethyl acetate (5 mL) 
and anhydrous ethanol (5 mL), was added a catalytic amount of Pd/C under a nitrogen atmosphere. The 
black suspension was degassed with nitrogen several times before being purged with hydrogen and being 
left to stir at room temperature, for one hour. The reaction mixture was filtered through a pad of Celite 
and washed with ethanol several times. Solvents were removed from the filtrate under reduced pressure 
to afford the product 11 as a white solid (770 mg, 99%), which was used without purification. δH 
(500MHz, DMSO) 9.30 (s, 1H, H-13), 8.59 (t, J = 5.2 Hz, 1H, H-6), 8.22 (s, 2H, H-1), 7.00 (d, J = 8.1 
Hz, 2H, H-10), 6.70 (d, J = 8.2 Hz, 2H, H-11), 5.49 (s, 1H, H-4), 3.74 (dd, J = 15.8, 8.5 Hz, 2H, H-7), 
3.69 – 3.60 (m, 1H, H-2), 3.35 – 3.17 (m, 2H, H-3), 2.62 (t, J = 7.2 Hz, 2H, H-8). δC (126MHz, DMSO) 
167.0 (C=O), 156.3 (C-Ar), 130.0 (CH-Ar), 129.6 (C-Ar), 115.6 (CH-Ar), 60.8 (CH2), 54.9 (CH), 41.3 
(CH2), 34.5 (CH2). MS (ES+) m/z 449.3 [2M+H]+, 471.2 [2M+Na]+. 
 (S)-4-Azido-N-(2-((3-hydroxy-1-((4-hydroxyphenethyl)amino)-1-oxopropan-2-yl)amino)-2-
oxoethyl)benzamide (12). Carboxylic acid 11 (100 mg, 0.454 mmol), triethylamine (0.32 mL, 2.270 
mmol) and PyBOP (236 mg, 0.454 mmol) were dissolved in a solution of anhydrous DMF (4 mL) and 
then stirred for five minutes, at room temperature, under a nitrogen atmosphere. Compound 18 (102 mg, 
0.454 mmol) was then added to the brown solution and stirred at room temperature, for 16 hours. The 
crude was diluted with water (50 mL) and the product was extracted into ethyl acetate (4 x 20 mL). The 
combined organic layers were dried over MgSO4, filtered and concentrated under reduced pressure to 
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afford a dark orange oil. Flash column chromatography (DCM:methanol 9:1) isolated the product 11 as a 
light cream solid (156 mg, 80%). δH (500 MHz, CD3OD) 7.91 (d, J = 8.8 Hz, 2H, H-2), 7.16 (d, J = 8.8 
Hz, 2H, H-3), 7.02 (d, J = 8.6 Hz, 2H, H-17), 6.69 (d, J = 8.5 Hz, 2H, H-18), 4.40 (t, J = 5.2 Hz, 1H, H-
9), 4.06 (ABq, J = 16.3 Hz, 2H, H-6), 3.78 (td, J = 11.1, 5.2 Hz, 2H, H-10), 3.36 (dd, J = 9.1, 6.6 Hz, 2H, 
H-14), 2.70 (t, J = 7.5 Hz, 2H, H-15). δC (126MHz, CD3OD) 170.7 (C=O), 170.6 (C=O), 168.3 (C=O), 
155.5 (C-Ar), 143.9 (C-Ar), 130.0 (C-Ar) 129.8 (C-Ar), 129.4 (CH-Ar), 129.1 (CH-Ar), 118.6 (CH-Ar), 
114.8 (CH-Ar), 61.5 (CH2), 55.6 (CH), 43.1 (CH2), 41.2 (CH2), 34.2 (CH2). MS (ES+) m/z 449.2 
[M+Na]+. HRMS (ESI) C20H23N6O5 calcd. 427.1730 [M+H]+, found 427.1731. HPLC (reverse-phase) 
MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, tR = 5.17 min (96.0%). Analytical data is in agreement 
with literature values.8  
 (S)-2-(2-(4-Azidobenzamido)acetamido)-3-((4-hydroxyphenethyl)amino)-3-oxopropyl dihydrogen 
phosphate (13). 
Step One. Synthesis of (S)-2-(2-(4-azidobenzamido)acetamido)-3-((4-hydroxyphenethyl)amino)-3-
oxopropyl di(N,N-diisopropylphosphonamidate). In a flame dried flask and under a nitrogen atmosphere, 
peptide 12 (144 mg, 0.338 mmol) was dissolved in a solution of anhydrous MeCN (7 mL) and anhydrous 
pyridine (3 mL). Tert-butyl magnesium chloride (0.75 mL, 0.743 mmol) and N,N,N′,N′-
tetramethylphosphorodiamidic chloride (0.05 mL, 0.338 mmol) was added and stirred for 24 h at room 
temperature. After reaction completion confirmed by TLC, the orange crude mixture was concentrated 
under reduced pressure and co-evaporated with methanol to azeotropically remove pyridine. The resulting 
orange oil was purified directly by flash column chromatography (DCM:methanol 95:5) to isolate the 
furnished diamidate as a cream solid (76 mg, 40%). δH (500MHz, CDCl3) 8.29 (s, 1H, H-6), 7.82 (d, J = 
8.2 Hz, 2H, H-2), 7.58 (d, J = 5.4 Hz, 1H, H-9), 7.26 (d, J = 9.1 Hz, 1H, H-14), 7.04 (d, J = 8.1 Hz, 2H, 
H-3), 6.99 – 6.90 (m, 4H, H-18 + H-19), 4.39 (s, 1H, H-10), 3.91 (d, J = 12.0 Hz, 2H, H-7), 3.72 – 3.66 
(m, 2H, H-11), 3.36 (dd, J = 11.9, 6.0 Hz, 2H, H-15), 2.74 – 2.60 (m, 14H, H-12 + H-16). δC (126MHz, 
CDCl3) 170.6 (C=O), 170.6 (C=O), 167.6 (C=O), 149.5 (C-Ar), 143.6 (C-Ar), 135.1 (C-Ar), 130.1 (CH-
Ar), 129.5 (C-Ar), 129.4 (CH-Ar), 120.1 (CH-Ar), 118.8 (CH-Ar), 62.2 (CH2), 55.0 (CH), 43.9 (CH2), 
40.6 (CH2), 36.6 (CH3), 34.3 (CH2). δP (202MHz, CDCl3) 10.53. MS (ES+) m/z 583.2 [M+Na]+.  
Step Two. Synthesis of (S)-2-(2-(4-azidobenzamido)acetamido)-3-((4-hydroxyphenethyl)amino)-3-
oxopropyl dihydrogen phosphate (13). To a solution of diamidate intermediate from the previous step (67 
mg, 0.120 mmol) in 1,4-dioxane (5 mL) was added 2N HCl solution (5 mL). The clear colourless/yellow 
solution was stirred at room temperature for 9 h. After TLC analysis confirmed total conversion, the 
mixture was concentrated under reduced pressure to afford the product 13 as a cream solid (55 mg, 91%). 
The product was then triturated with ethyl acetate (3 x 30 mL) and used without further purification. δH 
(500MHz, CD3OD) δ 7.94 (d, J = 8.7 Hz, 2H, H-2), 7.21 – 7.03 (m, 6H, H-3 + H-18 + H-19), 4.39 (t, J = 
5.1 Hz, 1H, H-10), 4.06 (ABq, J = 16.4 Hz, 2H, H-7), 3.78 (dd, J = 11.2, 5.3 Hz, 2H, H-11), 3.50 –  3.41 
(m, 2H, H-15), 2.77 (t, J = 6.2 Hz, 2H, H-16). δC (126MHz, DMSO) 170.2 (C=O), 169.5 (C=O), 166.2 
(C=O), 151.3 (C-Ar), 142.9 (C-Ar), 134.4 (C-Ar), 131.0 (C-Ar), 129.8 (CH-Ar), 129.8 (CH-Ar), 121.4 
(CH-Ar), 119.4 (CH-Ar), 62.0 (CH2), 55.8 (CH), 43.3 (CH2), 41.0 (CH2), 34.8 (CH2). δP (202MHz, 
CD3OD) -5.14. MS (ES+) m/z 507.1 [M+H]+. HRMS (ESI) C20H24N6O8P calcd. 507.1393 [M+H]+, 
found 507.1396. HPLC (reverse-phase) MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, tR = 5.66 min 
(87.6%). 
(S)-2-(2-(4-Azidobenzamido)acetamido)-3-((4-hydroxyphenethyl)amino)-3-oxopropyl diethyl 
phosphate (14). In a flame dried flask and under a nitrogen atmosphere, peptide 12 (60 mg, 0.141 mmol) 
was dissolved in a solution of anhydrous MeCN (7 mL) and anhydrous pyridine (3 mL). Tert-butyl 
magnesium chloride (0.28 mL, 0.282 mmol) and diethyl chlorophosphate (0.02 mL, 0.155 mmol) was 
added and stirred for 24 h at room temperature. After reaction completion confirmed by TLC, the orange 
crude mixture was concentrated under reduced pressure and co-evaporated with methanol to 
azeotropically remove pyridine. The resulting orange oil was purified directly by flash column 
chromatography (DCM:methanol 95:5) to isolate the furnished compound 14 as a colourless oil (24 mg, 
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30%). δH (500MHz, CDCl3) 7.92 (t, J = 5.2 Hz, 1H, H-6), 7.86 (d, J = 8.6 Hz, 2H, H-2), 7.32 (d, J = 7.6 
Hz, 1H, H-9), 7.11 (d, J = 8.5 Hz, 2H, H-3), 7.08 – 7.00 (m, 4H, H-19 + H-20), 6.93 (t, J = 5.7 Hz, 1H, 
H-15), 4.39 (dt, J = 7.8, 4.0 Hz, 1H, H-10), 4.28 – 4.16 (m, 4H, H-12), 4.10 – 3.82 (m, 3H, H-7 + H-
11a/b), 3.60 (dd, J = 11.3, 4.7 Hz, 1H, H-11a/b), 3.57 – 3.39 (m, 2H, H-16), 2.84 – 2.79 (m, 2H, H-17), 
1.38 (dd, J = 7.5, 6.6 Hz, 6H, H-13). δC (126MHz, CDCl3) 170.7 (C=O), 170.1 (C=O), 167.5 (C=O), 
149.1 (C-Ar), 143.8 (C-Ar), 135.7 (C-Ar), 130.2 (CH-Ar), 129.7 (C-Ar), 129.3 (CH-Ar), 120.1 (CH-Ar), 
118.9 (CH-Ar), 64.8 (CH2), 62.1 (CH2), 54.2 (CH), 44.1 (CH2), 40.2 (CH2), 34.3 (CH2), 16.1 (CH3). δP 
(202MHz, CDCl3) -6.11. MS (ES+) m/z 585.2 [M+Na]+. HRMS (ESI) C24H32N6O8P calcd. 563.2019 
[M+H]+, found 563.2034. HPLC (reverse-phase) MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, tR 
= 5.87 min (96%). 
Methyl (((S)-2-(2-(4-azidobenzamido)acetamido)-3-((4-hydroxyphenethyl)amino)-3-
oxopropoxy)(phenoxy)phosphoryl)-L-alaninate (15a). In a flame dried flask and under a nitrogen 
atmosphere, peptide 12 (50 mg, 0.117 mmol) was dissolved in a solution of anhydrous MeCN (7 mL) and 
anhydrous pyridine (3 mL). tert-Butyl magnesium chloride (tBuMgCl) (0.26 mL, 0.257 mmol) and 
chloridate 7 (36 mg, 0.129 mmol) was added and stirred for 24 h at room temperature. After reaction 
completion confirmed by TLC, the orange crude mixture was concentrated under reduced pressure and 
co-evaporated with methanol to azeotropically remove pyridine. The resulting orange oil was purified 
directly by flash column chromatography (DCM:methanol 95:5) to isolate the desired prodrug 15a as a 
cream solid (23 mg, 29%). δH (500MHz, CDCl3) 8.01 – 7.91 (m, 1H, H-6), 7.80 (dd, J = 11.2, 6.3 Hz, 
2H, H-2), 7.46 (dd, J = 11.3, 5.9 Hz, 1H, H-9), 7.33 (dd, J = 11.2, 7.5 Hz, 2H, H-14), 7.28 – 7.19 (m, 3H, 
H-13 + H-15), 7.13 – 6.97 (m, 5H, H-22 + H-26 + H-27), 6.94 (dd, J = 8.6, 3.7 Hz, 2H, H-3), 4.52 – 4.29 
(m, 2H, H-10 + H-16), 4.15 – 3.80 (m, 4H, H-7 + H-11a/b + H-17), 3.68 (d, J = 7.5 Hz, 3H, H-20), 3.63 
– 3.55 (m, 1H, H-11a/b), 3.46 – 3.36 (m, 2H, H-23), 2.75 (t, J = 6.3 Hz, 2H, H-24), 1.39 (d, J = 3.1 Hz, 
3H, H-18). δC (126MHz, CDCl3) 176.6 (C=O), 170.7 (C=O), 170.0 (C=O), 167.4 (C=O), 150.4 (C-Ar), 
148.9 (C-Ar), 143.7 (C-Ar), 135.8 (C-Ar), 130.2 (CH-Ar), 129.8 (CH-Ar), 129.7 (C-Ar), 129.3 (CH-Ar), 
125.4 (CH-Ar), 120.3 (CH-Ar), 120.2 (CH-Ar), 118.9 (CH-Ar), 62.2 (CH2), 54.2 (CH), 52.6 (CH3), 50.4 
(CH), 43.9 (CH2), 40.1 (CH2), 34.3 (CH2), 20.8 (CH3). δP (202MHz, CDCl3) -2.07, -2.13. MS (ES+) m/z 
690.2 [M+Na]+. HRMS (ESI) C30H35N7O9P calcd. 668.2234 [M+H]+, found 668.2230. HPLC (reverse-
phase) MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, tR = 6.20 min (96%). 
Isopropyl (((S)-2-(2-(4-azidobenzamido)acetamido)-3-((4-hydroxyphenethyl)amino)-3-
oxopropoxy)(phenoxy)phosphoryl)-L-alaninate (15b). In a flame dried flask and under a nitrogen 
atmosphere, peptide 12 (50 mg, 0.117 mmol) was dissolved in a solution of anhydrous MeCN (7 mL) and 
anhydrous pyridine (3 mL). tBuMgCl (0.26 mL, 0.257 mmol) and chloridate 20a (40 mg, 0.129 mmol) 
was added and stirred for 24 h at room temperature. After reaction completion confirmed by TLC, the 
orange crude mixture was concentrated under reduced pressure and co-evaporated with methanol to 
azeotropically remove pyridine. The resulting orange oil was purified directly by flash column 
chromatography (DCM:methanol 95:5) to isolate the furnished prodrug 15b as a cream solid (22 mg, 
27%). δH (500MHz, CDCl3) 7.97 (dd, J = 10.2, 4.4 Hz, 1H, H-6), 7.81 (dd, J = 8.5, 2.4 Hz, 2H, H-2), 7.45 
(dd, J = 12.9, 6.3 Hz, 1H, H-9), 7.36 – 7.30 (m, 2H, H-14), 7.25 – 7.14 (m, 3H, H-13 + H-15), 7.13 – 6.99 
(m, 5H, H-23 + H-27 + H-28), 6.93 (dd, J = 8.6, 3.6 Hz, 2H, H-3), 5.09 – 5.00 (m, 1H, H-20), 4.46 – 4.24 
(m, 2H, H-10 + H-16), 4.08 – 3.79 (m, 4H, H-7 + H-11a/b + H-17), 3.59 (d, J = 6.4 Hz, 1H, H-11a/b), 
3.41 (dt, J = 11.2, 6.4 Hz, 2H, H-24), 2.80 – 7.75 (m, 2H, H-25), 1.38 (dd, J = 6.9, 3.1 Hz, 3H, H-18), 
1.22 (dd, J = 5.3, 3.3 Hz, 6H, H-21). δC (126MHz, CDCl3) 172.8 (C=O), 170.6 (C=O), 170.1 (C=O), 
167.4 (C=O), 150.5 (C-Ar), 149.0 (C-Ar), 143.6 (C-Ar), 135.8 (C-Ar), 130.2 (CH-Ar), 129.8 (CH-Ar), 
129.7 (C-Ar), 129.3 (CH-Ar), 125.3 (CH-Ar), 120.3 (CH-Ar), 120.2 (CH-Ar), 118.9 (CH-Ar), 69.4 (CH), 
62.2 (CH2), 54.5 (CH), 50.5 (CH), 43.8 (CH2), 40.3 (CH2), 34.3 (CH2), 21.6 (CH3), 20.9 (CH3). δP 
(202MHz, CDCl3) -1.93, -2.03. MS (ES+) m/z 718.2 [M+Na]+. HRMS (ESI) C32H39N7O9P calcd. 
696.2547 [M+H]+, found 696.2541. HPLC (reverse-phase) MeOH/H2O 0:100 to 100:0 in 12 min, λ = 
254 nm, tR = 7.53 min (96.0%). 
 




oxopropoxy)(phenoxy)phosphoryl)-D-alaninate (15c). In a flame dried flask and under a nitrogen 
atmosphere, peptide 12 (160 mg, 0.375 mmol) was dissolved in a solution of anhydrous MeCN (7 mL) 
and anhydrous pyridine (3 mL). tBuMgCl (0.83 mL, 0.825 mmol) and chloridate 20b (133 mg, 0.375 
mmol) was added and stirred for 24 h at room temperature. After reaction completion confirmed by TLC, 
the orange crude mixture was concentrated under reduced pressure and co-evaporated with methanol to 
azeotropically remove pyridine. The resulting orange oil was purified directly by flash column 
chromatography (DCM:methanol 95:5) to isolate the desired prodrug 15c as a cream solid (58 mg, 29%). 
δH (500MHz, CDCl3) 7.90 (dd, J = 15.5, 5.0 Hz, 1H, H-6), 7.81 (dd, J = 9.6, 2.8 Hz, 2H, H-2), 7.43 – 
7.34 (m, 1H, H-9), 7.35 – 7.25 (m, 7H, H-14 + H-22 + H-23 + H-24), 7.24 – 7.13 (m, 3H, H-13 + H-15), 
7.08 – 6.97 (m, 5H, H-26 + H-30 + H-31), 6.93 (dd, J = 8.6, 4.4 Hz, 2H, H-3), 5.12 (dd, J = 5.9, 2.0 Hz, 
2H, H-20), 4.53 – 4.28 (m, 2H, H-10 + H-16), 4.12 (dd, J = 9.2, 4.9 Hz, 1H, H-17), 4.04 – 3.76 (m, 3H, 
H-7 + H-11a/b), 3.62 – 3.54 (m, 1H, H-11a/b), 3.46 – 3.40 (m, 2H, H-27), 2.84 – 2.64 (m, 2H, H-28), 
1.40 (dd, J = 6.7, 2.4 Hz, 3H, H-18). δC (126MHz, CDCl3) 173.1 (C=O), 170.6 (C=O), 170.0 (C=O), 
167.4 (C=O), 150.4 (C-Ar), 148.9 (C-Ar), 143.6 (C-Ar), 135.8 (C-Ar), 135.1 (C-Ar), 130.2 (CH-Ar), 
129.8 (CH-Ar), 129.7, (C-Ar) 129.3 (CH-Ar), 128.7 (CH-Ar), 128.6 (CH-Ar), 128.2 (CH-Ar), 125.4 (CH-
Ar), 120.3 (CH-Ar), 120.2 (CH-Ar), 118.9 (CH-Ar), 67.4 (CH2), 62.2 (CH2), 54.4 (CH), 50.5 (CH), 43.8 
(CH2), 40.3 (CH2), 34.3 (CH2), 20.8 (CH3). δP (202MHz, CDCl3) -2.03, -2.13. MS (ES+) m/z 766.2 
[M+Na]+. HRMS (ESI) C36H39N7O9P calcd. 744.2547 [M+H]+, found 744.2548. HPLC (reverse-phase) 
MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, tR = 8.64 min (95.3%). 
Ethyl (4-azidobenzoyl)glycinate (17). 4-Azidobenzoic acid 16 (322 mg, 2.000 mmol) was dissolved in 
anhydrous DCM (20 mL) and stirred with DIPEA (0.77 mL, 4.400 mmol) for five minutes at room 
temperature. PyBOP (1.145 g, 2.200 mmol) and glycine ethyl ester hydrochloride (307 mg, 2.200 mmol) 
was added to the colourless solution at 0 oC and stirred at room temperature for 3 h. Water (20 mL) was 
then poured into the yellow solution and the product was extracted into DCM washes (2 x 20 mL), dried 
over MgSO4, filtered and concentrated under reduced pressure to afford an orange oil. The oil was purified 
via flash column chromatography (ethyl acetate:hexane 1:1) to yield the amide 17 as a white solid (455 
mg, 92%). δH (500MHz, CDCl3) 7.82 (d, J = 8.2 Hz, 2H, H-3), 7.08 (d, J = 8.2 Hz, 2H, H-2), 6.60 (s, 1H, 
H-6), 4.27 (q, J = 7.1 Hz, 2H, H-9), 4.23 (d, J = 4.8 Hz, 2H, H-7), 1.32 (t, J = 7.1 Hz, 3H, H-10). δC 
(126MHz, CDCl3) 170.1 (C=O), 166.3 (C=O), 143.7 (C-Ar), 130.2 (C-Ar), 128.9 (CH-Ar), 119.1 (CH-
Ar), 61.8 (CH2), 41.9 (CH2), 14.2 (CH3). MS (ES+) m/z 271.1 [M+Na]+, 519.2 [2M+Na]+.  
Analytical data is in agreement with literature values.9  
(4-Azidobenzoyl)glycine (18). To a stirring solution of azide 17 (300 mg, 1.218 mmol) in THF (8 mL), 
10% NaOH (30 mg, 1.218 mmol) was added and stirred at room temperature for 1 h. After TLC confirmed 
reaction completion, the orange solution was concentrated under reduced pressure and diluted with water 
(20 mL) and carefully acidified to pH with 6N HCl, forming a white suspension. The product was 
extracted out of the suspension with ethyl acetate (3 x 20 mL), died under MgSO4, filtered and 
concentrated under reduced pressure to yield the desired acid 18 as a white solid (263 mg, 98%).  
δH (500MHz, CD3OD) 7.90 (d, J = 8.2 Hz, 2H, H-3), 7.16 (d, J = 8.3 Hz, 2H, H-2), 4.08 (d, J = 4.5 Hz, 
2H, H-7). δC (126MHz, CD3OD) 171.7 (C=O), 168.0 (C=O), 143.7 (C-Ar), 130.2 (C-Ar), 128.9 (CH-Ar), 
118.6 (CH-Ar), 40.9 (CH2). MS (ES-) m/z 215.1 [M-H]-. Analytical data is in agreement with literature 
values.9  
Isopropyl (chloro(phenoxy)phosphoryl)-L-alaninate (20a). To a stirring solution of compound 5 (0.30 
mL, 1.969 mmol) and anhydrous DCM (10 mL), in a flame dried flask, was added L-alanine isopropyl 
ester hydrochloride (300 mg, 1.790 mmol) and stirred for 15 minutes at room temperature, under a 
nitrogen atmosphere. Anhydrous triethylamine (0.51 mL, 3.580 mmol) was added dropwise to the yellow 
solution at -78 oC to form a suspended white precipitate. The reaction mixture was stirred for 30 minutes 
at -78°C before being left to stir and warm up to room temperature over 2.5 hours. Upon reaction 
completion, the colourless solution was concentrated under reduced pressure, and then diethyl ether was 
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added to the obtained material. After gentle mixing and filtration,  the yellow filtrate was concentrated 
under reduced pressure to afford a colourless oil, which was purified with column chromatography (ethyl 
acetate:hexane 6:4) to yield compound 20a as a yellow oil (463 mg, 86%).  δH (500MHz, CDCl3) 7.38 (t, 
J = 9.0 Hz, 2H, H-3), 7.29 – 7.18 (m, 3H, H-2 + H-4), 5.19 – 5.00 (m, 1H, H-9), 4.36 – 3.94 (m, 2H, H-
5 + H-6), 1.49 (d, J = 2.3 Hz, 3H, H-7), 1.27 (dd, J = 8.0, 6.2 Hz, 6H, H-10). δP (202MHz, CDCl3) 8.04, 
7.65. Analytical data is in agreement with literature values.10  
Benzyl (chloro(phenoxy)phosphoryl)-L-alaninate (20b). To a stirring solution of compound 5 (0.23 
mL, 1.530 mmol) and anhydrous DCM (10 mL), in a flame dried flask, was added L-alanine benzyl ester 
hydrochloride (300 mg, 1.391 mmol) and stirred for 15 minutes at room temperature, under a nitrogen 
atmosphere. Anhydrous triethylamine (0.39 mL, 2.782 mmol) was added dropwise to the yellow solution 
at -78 oC to form a suspended white precipitate. The reaction mixture was stirred for 30 minutes at -78°C 
before being left to stir and warm up to room temperature over 2.5 hours. Upon reaction completion, the 
colourless solution was concentrated under reduced pressure, and then diethyl ether was added to the 
obtained material. After gentle mixing and filtration,  the yellow filtrate was concentrated under reduced 
pressure to afford a colourless oil, which was purified with column chromatography (ethyl acetate:hexane 
6:4) to yield compound 20b as a yellow oil (410 mg, 83%). δH (500MHz, CDCl3) 7.45 – 7.28 (m, 7H, H-
3 + H-11 + H-12 + H-13), 7.28 – 7.21 (m, 3H, H-2 + H-4), 5.21 (d, J = 7.7 Hz, 2H, H-9), 4.36 – 4.12 (m, 
2H, H-5 + H-6), 1.52 (dd, J = 6.8, 3.0 Hz, 3H, H-7). δP (202MHz, CDCl3) 7.84, 7.49. Analytical data is 
in agreement with literature values.10  
 
REFERENCES 
1. Mehellou, Y.; Valente, R.; Mottram, H.; Walsby, E.; Mills, K. I.; Balzarini, J.; McGuigan, C. Phosphoramidates of 2'-beta-D-arabinouridine 
(AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. Bioorg. Med. Chem. 2010, 18, 2439-46. 
2. Lima, C. D.; Klein, M. G.; Hendrickson, W. A. Structure-based analysis of catalysis and substrate definition in the HIT protein family. Science  
1997, 278, 286-90. 
3. Hawkins, P. C.; Nicholls, A. Conformer generation with OMEGA: learning from the data set and the analysis of failures. J. Chem. Inf. Model. 
2012, 52, 2919-36. 
4. McGann, M. FRED pose prediction and virtual screening accuracy. J. Chem. Inf. Model. 2011, 51, 578-96. 
5. McGann, M. R.; Almond, H. R.; Nicholls, A.; Grant, J. A.; Brown, F. K. Gaussian docking functions. Biopolymers 2003, 68, 76-90. 
6. Meneghesso, S.; Vanderlinden, E.; Brancale, A.; Balzarini, J.; Naesens, L.; McGuigan, C. Synthesis and biological evaluation of purine 2'-
fluoro-2'-deoxyriboside ProTides as anti-influenza virus agents. ChemMedChem 2013, 8, 415-25. 
7. Qi, X. L.; Yang, E. Q.; Zhang, J. T.; Wang, T.; Cao, X. P. A Facile Synthesis of the Spiroindoline-Based Growth Hormone Secretagogue, 
MK-677. Chinese Chem. Lett. 2012, 23, 661-664. 
8. Wu, H.; Ge, J.; Yao, S. Q. Microarray-assisted high-throughput identification of a cell-permeable small-molecule binder of 14-3-3 proteins. 
Angew. Chem. Int. Ed. Engl. 2010, 49, 6528-32. 
9. Arrendale, A.; Kim, K.; Choi, J. Y.; Li, W.; Geahlen, R. L.; Borch, R. F. Synthesis of a phosphoserine mimetic prodrug with potent 14-3-3 
protein inhibitory activity. Chem. Biol. 2012, 19, 764-71. 
10. Osgerby, L.; Lai, Y. C.; Thornton, P. J.; Amalfitano, J.; Le Duff, C. S.; Jabeen, I.; Kadri, H.; Miccoli, A.; Tucker, J. H. R.; Muqit, M. M. K.; 
Mehellou, Y. Kinetin Riboside and Its ProTides Activate the Parkinson's Disease Associated PTEN-Induced Putative Kinase 1 (PINK1) 


























          
16 
 
NMR SPECTRA AND HPLC DATA 
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Compound 16d 
Compound 15c 
